semaglutide deaths 2024 The letter cited three among patients using semaglutide, the active ingredient in several of its weight-loss medications, which it said were not properly investigated or reported. Read more at the link GLP-1-based therapy for obesity -

This product is not intended for type 1 diabetes and is not a substitute for insulin when insulin is required

Semaglutide is one of the most widely studied GLP-1 medications and remains a foundational option for medical weight management

And similar to other programs, reviews are also a tad mixed, with some users reporting less-than-thrilled experiences and others citing positive experiences

Novel pathway for LPS-induced afferent vagus nerve activation: Possible role of nodose ganglion

The recent explosion in irresponsible and misleading advertising about compounded GLP-1 drugs, like the Hims & Hers Super Bowl commercial, puts patients safety at risk and we cannot stay silent, the drugmaker said in a statement sent to Fierce Pharma Marketing